Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-MGS5 vs 68Ga-DOTATATE PET/CT in Medullary Thyroid Carcinoma
NCT06520319Phase 1Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-EVG321 in medullary thyroid carcinoma (MTC), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Maximum Standardized Uptake Value at 2 years and Peak Standardized Uptake Value at 2 years. Started Jun 2023; status: recruiting.
02
Drugs
68Ga-EVG321
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT06520319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520319.